Chinemerem M Emeasoba

Researcher

Last publication 2026 Last refreshed 2026-05-02

faculty

1 h-index 21 pubs 7 cited

Research Areas

OverviewAI-generated summary

Chinemerem M Emeasoba's research investigates patterns of disease, treatment efficacy, and patient outcomes across various medical conditions. Emeasoba has examined the survivability of immunotherapy in colon cancer management and analyzed the occurrence of myocardial infarction, deep venous thrombosis, and pulmonary embolism in patients hospitalized with SARS-CoV-2. Further work includes characterizing palliative care utilization among patients with Acute Myeloid Leukemia (AML) and exploring differential neurotoxicity patterns in neuroendocrine tumors. Emeasoba has also contributed to understanding the mechanisms of immune evasion in cancer, specifically how tumor cells and immunotherapy can reprogram bone marrow niches to induce hematopoietic dysfunction and therapy-related myeloid neoplasms. Additionally, research has explored reprogramming tumor metabolism to overcome immune evasion in non-small cell lung cancer by blocking GLUT1 in conjunction with PD1/CTLA-4 therapy. Collaborations include work with Hanne Jensen, Cade Richesin, Samantha Robinson, and Kingsley Chinonyerem Nnawuba at the University of Arkansas at Fayetteville.

Metrics

h-index: 1
Publications: 21
Citations: 7

Selected Publications

HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap (2026)

DOI OpenAlex
HSR26-266: Navigating the Burden of Cure: Defining Survivorship Pathways in Head and Neck Cancer (2026)

DOI OpenAlex
BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer (2026)

DOI OpenAlex
Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises (2026)

DOI OpenAlex
Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer. (2026)

DOI OpenAlex
Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients. (2026)

DOI OpenAlex
495 Breaking the recurrence barrier in colon cancer: ATOMIC trial doubles disease-free survival with atezolizumab+mFOLFOX6 (2025)

DOI OpenAlex
1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles (2025)

DOI OpenAlex
776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms (2025)

DOI OpenAlex
426 Reprogramming tumor metabolism to overcome immune evasion: GLUT1 blockade synergizes with PD1/CTLA-4 therapy in non-small cell lung cancer (2025)

DOI OpenAlex
Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. (2025)

DOI OpenAlex
Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer. (2025)

DOI OpenAlex